AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Indaptus Therapeutics Inc (NASDAQ:INDP)
2.21 USD
+0.060 2.791%Sponsored Reports
Loading...
| Previous Close (in USD) | 2.15 |
|---|---|
| Change | +0.060 2.791% |
| 52 W H/L (in USD) | 4.080/1.560 |
| EBITDA (in USD) | -16.377M |
| PE Ratio | -- |
| Volume | 97913 |
| Diluted Eps TTM | -1.77 |
| Total Assets (in USD) | 14.924M |
|---|---|
| Total Liabilities (in USD) | 2.847M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 13.362M |
| Market Cap (in USD) | 20.237 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Employees: 7
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Jeffrey A. Meckler | CEO & Director | 1967 |
| 2. | Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer & Director | 1956 |
| 3. | Mr. Walt Addison Linscott Esq. | Chief Bus. Officer | 1961 |
| 4. | Mr. Nir Sassi | CFO, Sec. & Treasurer | 1976 |
| 5. | Dr. Boyan Vesselinov Litchev M.D. | Chief Medical Officer | 1967 |
| 6. | Mr. Walt Addison Linscott Esq. | Chief Operating Officer | 1961 |
| 7. | Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer & Director | 1957 |
| 8. | Mr. Nir Sassi | CFO, Secretary & Treasurer | 1976 |
| 9. | Dr. Roger J. Waltzman M.B.A., M.D. | Chief Medical Officer | 1969 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -14.323M | -7.711M | -3.584M | - |
| Minority Interest | - | - | - | - |
| Net Income | -13.735M | -7.694M | -3.569M | - |
| Selling General Administrative | 8.586M | 5.206M | 0.944M | - |
| Gross Profit | - | - | - | - |
| Reconciled Depreciation | 0.002M | 0.001M | 0.001M | - |
| Ebit | -14.911M | -7.729M | -3.599M | -2.632M |
| Ebitda | -14.909M | -7.728M | -3.598M | - |
| Depreciation And Amortization | 0.002M | 0.001M | 0.001M | - |
| Operating Income | -14.911M | -7.729M | -3.599M | - |
| Other Operating Expenses | 14.911M | 7.729M | 3.599M | - |
| Interest Expense | 0.588M | 0.018M | 0.015M | 0M |
| Tax Provision | - | - | - | - |
| Interest Income | 0.588M | 0.018M | 0.015M | - |
| Net Interest Income | 0.588M | 0.018M | 0.015M | - |
| Income Tax Expense | -0.588M | -0.018M | -0.015M | - |
| Total Revenue | 0M | 0M | 0M | - |
| Total Operating Expenses | 14.911M | 7.729M | 3.599M | - |
| Cost Of Revenue | - | - | - | - |
| Total Other Income Expense Net | 0.588M | 0.018M | 0.015M | - |
| Net Income From Continuing Ops | -14.323M | -7.711M | -3.584M | - |
| Net Income Applicable To Common Shares | -14.323M | -7.711M | -3.584M | -2.565M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 14.924M | 28.064M | 40.577M | 1.778M | - |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 0.633M | 0.811M | 1.234M | 0.095M | 0.038M |
| Total Liab | 2.847M | 3.433M | 4.677M | 2.015M | - |
| Total Stockholder Equity | 12.076M | 24.63M | 35.9M | -0.238M | - |
| Other Current Liab | 1.866M | 1.975M | 1.87M | 1.86M | 0.25M |
| Common Stock | 0.084M | 0.084M | 0.083M | 0.019M | 0.001M |
| Capital Stock | 0.084M | 0.084M | 0.083M | 0.028M | - |
| Retained Earnings | -45.417M | -29.994M | -15.671M | -7.96M | -4.375M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.738M | 0.016M | 0.044M | 0.046M |
| Cash | 13.362M | 9.627M | 39.132M | 1.637M | - |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 2.774M | 3.433M | 4.604M | 2.015M | 0.734M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -13.187M | -9.546M | -38.963M | -1.637M | - |
| Short Term Debt | 0.102M | 0.08M | 0.096M | 0.096M | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 0.175M | 0.08M | 0.169M | 0.169M | - |
| Other Stockholder Equity | 57.41M | 54.444M | 51.488M | 7.694M | - |
| Property Plant Equipment | - | 0.081M | 0.173M | 0.001M | 0.002M |
| Total Current Assets | 13.995M | 27.244M | 40.387M | 1.732M | 3.896M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 0M | 16.806M | - | - | - |
| Net Receivables | - | - | 0.021M | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 0.806M | 1.378M | 2.638M | 0.156M | 0.025M |
| Accumulated Other Comprehensive Income | 0M | 0.096M | - | - | - |
| Non Currrent Assets Other | 0.755M | 0.738M | 0.016M | 0.044M | - |
| Non Current Assets Total | 0.929M | 0.82M | 0.189M | 0.046M | - |
| Capital Lease Obligations | 0.175M | 0.08M | 0.169M | 0M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | -16.427M | 0.448M | -16.6M | -16.6M |
| Total Cashflows From Investing Activities | -16.427M | 0.448M | 0.448M | -0.003M |
| Total Cash From Financing Activities | 0M | 48.337M | 1.163M | 0.25M |
| Net Income | -14.323M | -7.711M | -3.584M | -2.565M |
| Change In Cash | -29.505M | 37.495M | -2.161M | -1.884M |
| Begin Period Cash Flow | 39.132M | 1.637M | 3.799M | - |
| End Period Cash Flow | 9.627M | 39.132M | 1.637M | 3.799M |
| Total Cash From Operating Activities | -13.078M | -11.291M | -3.325M | -2.132M |
| Depreciation | 0.002M | 0.001M | 0.001M | 0M |
| Other Cashflows From Investing Activities | 0.173M | 0.452M | 0.452M | 0.452M |
| Dividends Paid | - | - | - | - |
| Change To Inventory | - | - | - | - |
| Sale Purchase Of Stock | - | - | - | - |
| Other Cashflows From Financing Activities | -16.427M | 43.337M | 48.337M | 0.25M |
| Capital Expenditures | 0M | 0.004M | 0.004M | 0.003M |
| Change In Working Capital | -1.58M | -5.091M | 0.119M | - |
| Other Non Cash Items | -0.134M | - | -5.091M | - |
| Free Cash Flow | -13.078M | -11.294M | -3.325M | - |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 229197 |
| 2. | Fidelity Extended Market Index | 2 years ago | 27996 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 27068 |
| 4. | Fidelity Nasdaq Composite Index | 2 years ago | 14123 |
| 5. | Fidelity Series Total Market Index | 2 years ago | 9314 |
| 6. | SSgA U.S. Extended Market Index Class I | 2 years ago | 6400 |
| 7. | NT Ext Equity Mkt Idx Fd - NL | 2 years ago | 5997 |
| 8. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 2 years ago | 4816 |
| 9. | NT Ext Equity Mkt Idx Fd - L | 2 years ago | 3590 |
| 10. | Northern Trust Extended Eq Market Idx | 2 years ago | 3590 |
| 11. | SSgA U.S. Total Market Index Strategy | 2 years ago | 1846 |
| 12. | Spartan Total Market Index Pool E | 2 years ago | 1826 |
| 13. | Spartan Extended Market Index Pool E | 2 years ago | 1481 |
| 14. | NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 2 years ago | 194 |
| 15. | Target 10/90 IL | 2 years ago | 43 |
| 16. | Fidelity U.S. Equity Index Ins Trust | 2 years ago | 27 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 2 years ago | 256265 |
| 2. | Investment House LLC | 2 years ago | 102437 |
| 3. | Geode Capital Management, LLC | 2 years ago | 54767 |
| 4. | Strategy Asset Managers LLC | 2 years ago | 45336 |
| 5. | Pine Valley Investments Ltd Liability Co | 2 years ago | 44240 |
| 6. | Renaissance Technologies Corp | 2 years ago | 29400 |
| 7. | Vivaldi Capital Management, LLC | 2 years ago | 24000 |
| 8. | State Street Corporation | 2 years ago | 19473 |
| 9. | Tower Research Capital LLC | 2 years ago | 4696 |
| 10. | UBS Group AG | 2 years ago | 3699 |
| 11. | Morgan Stanley - Brokerage Accounts | 2 years ago | 884 |
| 12. | Bangor Savings Bank | 2 years ago | 400 |
| 13. | Wells Fargo & Co | 2 years ago | 104 |
| 14. | Royal Bank of Canada | 2 years ago | 38 |
| 15. | JPMorgan Chase & Co | 2 years ago | 9 |
| 16. | Group One Trading, LP | 2 years ago | 7 |
| 17. | Bank of America Corp | 2 years ago | 3 |
| 18. | Qube Research & Technologies | 2 years ago | 1 |
| 19. | Northern Trust Corp | 2 years ago | 0 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...